• 1
    Haynes BF, Hemler ME, Mann DL et al. Characterization of a monoclonal antibody (4F2) that binds to human monocytes and to a subset of activated lymphocytes. J Immunol 1981; 126: 140914.
  • 2
    Hashimoto Y, Masuko T, Yagita H, Endo N, Kanazawa J, Tazawa J. A proliferation-associated rat cell surface antigen recognized by a murine monoclonal antibody. Gann 1983; 74: 81921.
  • 3
    Luscher B, Rousseaux M, Lees R et al. Cell surface glycoproteins involved in the stimulation of interleukin 1-dependent interleukin 2 production by a subline of EL-4 thymoma cells. II. Structure, Biosynthesis, and Maturation. J Immunol 1985; 135: 39517.
  • 4
    Mastroberardino L, Spindler B, Pfeiffer R et al. Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a permease family. Nature 1998a; 395: 28891.
  • 5
    Kanai Y, Segawa H, Miyamoto K et al. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 1998; 273: 2362932.
  • 6
    Bertran J, Magagnin S, Werner A et al. Stimulation of system y(+)-like amino acid transport by the heavy chain of human 4F2 surface antigen in Xenopus laevis oocytes. Proc Natl Acad Sci USA 1992; 89: 560610.
  • 7
    Wells RG, Lee WS, Kanai Y, Leiden JM, Hediger MA. The 4F2 antigen heavy chain induces uptake of neutral and dibasic amino acids in Xenopus oocytes. J Biol Chem 1992; 267: 152858.
  • 8
    Mastroberardino L, Spindler B, Pfeiffer R et al. Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a permease family. Nature 1998b; 395: 28891.
  • 9
    Pfeiffer R, Rossier G, Spindler B, Meier C, Kuhn L, Verrey F. Amino acid transport of y+L-type by heterodimers of 4F2hc/CD98 and members of the glycoprotein-associated amino acid transporter family. EMBO J 1999; 18: 4957.
  • 10
    Sato H, Tamba M, Ishii T, Bannai S. Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J Biol Chem 1999; 274: 114558.
  • 11
    Liu X, Charrier L, Gewirtz A, Sitaraman S, Merlin D. CD98 and intracellular adhesion molecule I regulate the activity of amino acid transporter LAT-2 in polarized intestinal epithelia. J Biol Chem 2003; 278: 236727.
  • 12
    Rajan DP, Kekuda R, Huang W et al. Cloning and expression of a b(0,+)-like amino acid transporter functioning as a heterodimer with 4F2hc instead of rBAT. A new candidate gene for cystinuria. J Biol Chem 1999; 274: 2900510.
  • 13
    Fukasawa Y, Segawa H, Kim JY et al. Identification and characterization of a Na(+)-independent neutral amino acid transporter that associates with the 4F2 heavy chain and exhibits substrate selectivity for small neutral D- and L-amino acids. J Biol Chem 2000; 275: 96908.
  • 14
    Dong S, Hughes RC. Galectin-3 stimulates uptake of extracellular Ca2+ in human Jurkat T-cells. FEBS Lett 1996; 395: 1659.
  • 15
    Posillico JT, Srikanta S, Eisenbarth G, Quaranta V, Kajiji S, Brown EM. Binding of monoclonal antibody (4F2) to its cell surface antigen on dispersed adenomatous parathyroid cells raises cytosolic calcium and inhibits parathyroid hormone secretion. J Clin Endocrinol Metab 1987; 64: 4350.
  • 16
    Michalak M, Quackenbush EJ, Letarte M. Inhibition of Na+/Ca2+ exchanger activity in cardiac and skeletal muscle sarcolemmal vesicles by monoclonal antibody 44D7. J Biol Chem 1986; 261: 925.
  • 17
    Warren AP, Patel K, McConkey DJ, Palacios R. CD98: a type II transmembrane glycoprotein expressed from the beginning of primitive and definitive hematopoiesis may play a critical role in the development of hematopoietic cells. Blood 1996; 87: 367687.
  • 18
    Ohgimoto S, Tabata N, Suga S et al. Molecular characterization of fusion regulatory protein-1 (FRP-1) that induces multinucleated giant cell formation of monocytes and HIV gp160-mediated cell fusion. FRP-1 and 4F2/CD98 are identical molecules. J Immunol 1995; 155: 358592.
  • 19
    Suga S, Tsurudome M, Ohgimoto S et al. Identification of fusion regulatory protein (FRP)-1/4F2 related molecules: Cytoskeletal proteins are associated with FRP-1 molecules that regulate multinucleated giant cell formation of monocytes and HIV-induced cell fusion. Cell Struct Funct 1995; 20: 47383.
  • 20
    Fenczik CA, Sethi T, Ramos JW, Hughes PE, Ginsberg MH. Complementation of dominant suppression implicates CD98 in integrin activation. Nature 1997; 390: 815.
  • 21
    Macdonald HR, Lees RK, Bron C. Cell surface glycoproteins involved in the stimulation of interleukin 1-dependent interleukin 2 production by a subline of EL-4 thymoma cells. I. Functional characterization by monoclonal antibodies. J Immunol 1985; 135: 394450.
  • 22
    Patterson JA, Eisinger M, Haynes BF, Berger CL, Edelson RL. Monoclonal antibody 4F2 reactive with basal layer keratinocytes: studies in the normal and a hyperproliferative state. J Invest Dermatol 1984; 83: 2103.
  • 23
    Masuko T, Abe J, Yagita H, Hashimoto Y. Human bladder cancer cell-surface antigens recognized by murine monoclonal antibodies raised against T24 bladder cancer cells. Jpn J Cancer Res 1985a; 76: 38694.
  • 24
    Yagita H, Masuko T, Takahashi N, Hashimoto Y. Monoclonal antibodies that inhibit activation and proliferation of lymphocytes. I. Expression of the antigen on monocytes and activated lymphocytes. J Immunol 1986a; 136: 205561.
  • 25
    Tanaka T, Masuko T, Hashimoto Y. Appearance of a proliferation-associated antigen, gp125, on rat and human lymphocytes by co-stimulation with phorbol ester and calcium ionophore. J Biochem 1988; 103: 6449.
  • 26
    Masuko T, Abe J, Yagita H, Hashimoto Y. Human bladder cancer cell-surface antigens recognized by murine monoclonal antibodies raised against T24 bladder cancer cells. Jpn J Cancer Res 1985b; 76: 38694.
  • 27
    Yagita H, Masuko T, Hashimoto Y. Inhibition of tumor cell growth in vitro by murine monoclonal antibodies that recognize a proliferation-associated cell surface antigen system in rats and humans. Cancer Res 1986b; 46: 147884.
  • 28
    Itoh K, Inoue K, Hirooka K et al. Phage display cloning and characterization of monoclonal antibody genes and recombinant Fab fragment against the CD98 oncoprotein. Jpn J Cancer Res 2001; 92: 131321.
  • 29
    Itoh K, Ohshima M, Sonobe M et al. Antibody epitope peptides as potential inducers of IgG antibodies against CD98 oncoprotein. Cancer Sci 2009; 100: 12631.
  • 30
    Tanaka T, Suzuki S, Masuko T, Hashimoto Y. In vitro targeting and cytotoxicity of adriamycin in liposomes bearing monoclonal antibody against rat or human gp125 cell proliferation-associated antigen. Jpn J Cancer Res 1989; 80: 3806.
  • 31
    Hara K, Kudoh H, Enomoto T et al. Malignant transformation of NIH3T3 cells by overexpression of early lymphocyte activation antigen CD98. Biochem Biophys Res Commun 1999; 262: 7205.
  • 32
    Shishido T, Uno S, Kamohara M et al. Transformation of BALB3T3 cells caused by over-expression of rat CD98 heavy chain (HC) requires its association with light chain: mis-sense mutation in a cysteine residue of CD98HC eliminates its transforming activity. Int J Cancer 2000a; 87: 3116.
  • 33
    Hara K, Kudoh H, Enomoto T et al. Enhanced tumorigenicity caused by truncation of the extracellular domain of GP125/CD98 heavy chain. Oncogene 2000; 19: 620915.
  • 34
    Ohkawa M, Ohno Y, Takeuchi A et al. Oncogenic character of L-type amino-acid transporter 1 (LAT1) revealed by the targeted disruption of LAT1 gene in chicken DT40 cells. Biochem Biophys Res Commun 2011; 406: 64955.
  • 35
    Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 32330.
  • 36
    Morgan DO. Principles of CDK regulation. Nature 1995; 374: 1314.
  • 37
    Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493501.
  • 38
    Yagi H, Masuko T. Multi-color flow cytometric analysis using UV-excited fluorochromes: study on the expression of CD98 amino-acid transporter. Cytometry Res 2002; 12: 6572.
  • 39
    Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes 1995; 9: 114963.
  • 40
    Hengst L, Reed SI. Translational control of p27Kip1 accumulation during the cell cycle. Science 1996; 271: 18614.
  • 41
    Meikrantz W, Schlegel R. Suppression of apoptosis by dominant negative mutants of cyclin-dependent protein kinases. J Biol Chem 1996; 271: 102059.
  • 42
    Kranenburg O, van der Eb AJ, Zantema A. Cyclin D1 is an essential mediator of apoptotic neuronal cell death. EMBO J 1996; 15: 4654.
  • 43
    Gil-Gomez G, Berns A, Brady HJ. A link between cell cycle and cell death: Bax and Bcl-2 modulate Cdk2 activation during thymocyte apoptosis. EMBO J 1998; 17: 720918.
  • 44
    Sugiyama K, Akiyama T, Shimizu M et al. Decrease in susceptibility toward induction of apoptosis and alteration in G1 checkpoint function as determinants of resistance of human lung cancer cells against the antisignaling drug UCN-01 (7-Hydroxystaurosporine). Cancer Res 1999; 59: 440612.
  • 45
    Leach SD, Scatena CD, Keefer CJ et al. Negative regulation of Wee1 expression and Cdc2 phosphorylation during p53-mediated growth arrest and apoptosis. Cancer Res 1998; 58: 32316.
  • 46
    Levkau B, Koyama H, Raines EW et al. Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: role of a caspase cascade. Mol Cell 1998; 1: 55363.
  • 47
    Han EK, Begemann M, Sgambato A et al. Increased expression of cyclin D1 in a murine mammary epithelial cell line induces p27kip1, inhibits growth, and enhances apoptosis. Cell Growth Differ 1996; 7: 699710.
  • 48
    Hunter T. Oncoprotein networks. Cell 1997; 88: 33346.
  • 49
    Nobori T, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368: 7536.
  • 50
    Afrakhte M, Heldin NE, Westermark B. Inhibition of G1 cyclin-dependent kinase activity in cell density-dependent growth arrest in human fibroblasts. Cell Growth Differ 1998; 9: 9838.
  • 51
    Bohmer RM, Scharf E, Assoian RK. Cytoskeletal integrity is required throughout the mitogen stimulation phase of the cell cycle and mediates the anchorage-dependent expression of cyclin D1. Mol Biol Cell 1996; 7: 10111.
  • 52
    Zhu X, Ohtsubo M, Bohmer RM, Roberts JM, Assoian RK. Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. J Cell Biol 1996; 133: 391403.
  • 53
    Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 1125.
  • 54
    Rintoul RC, Buttery RC, Mackinnon AC et al. Cross-linking CD98 promotes integrin-like signaling and anchorage-independent growth. Mol Biol Cell 2002; 13: 284152.
  • 55
    Kim SM, Hahn J-H. CD98 activation increases surface expression and clustering of β1 integrins in MCF-7 cells through FAK/Src- and cytoskeleton-independent mechanisms. Exp Mol Med 2008; 40: 26170.
  • 56
    Feral CC, Zijlstra A, Tkachenko E et al. CD98hc (SLC3A2) participates in fibronectin matrixassembly by mediating integrin signaling. J Cell Biol 2007; 178: 70111.
  • 57
    Henderson NC, Collis EA, Mackinnon AC et al. CD98hc (SLC3A2) Interaction with β1 Integrins Is Required for Transformation. J Biol Chem 2004; 279: 5473141.
  • 58
    Shishido T, Ohkawa M, Itoh A, Enomoto T, Hashimoto Y, Masuko T. Colocalization of GP125/CD98 with tropomyosin isoforms at the cell–cell adhesion boundary. J Biochem 2000b; 127: 25361.
  • 59
    Masuko T, Ohno Y, Masuko K et al. Towards therapeutic monoclonal antibodies to membrane oncoproteins by a robust strategy using rats immunized with transfectants expressing target molecules fused to green fluorescent protein. Cancer Sci 2011; 102: 2535.
  • 60
    Ishimoto T, Nagano O, Yae T et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc and thereby promotes tumor growth. Cancer Cell 2011; 19: 387400.
  • 61
    Ohno Y, Suda K, Masuko K, Yagi H, Hashimoto Y, Masuko T. Production and characterization of highly tumor-specific rat monoclonal antibodies recognizing the extracellular domain of human LAT1 amino-acid transporter. Cancer Sci 2008; 99: 10007.
  • 62
    Ishimoto T, Ohshima H, Ohshima M et al. CD44+ slow-cycling tumor cell expansion is triggered by the cooperative actions of Wnt and prostaglandin E2 in gastric tumorigenesis. Cancer Sci 2010; 101: 6738.
  • 63
    Masuko K, Okazaki S, Satoh M et al. Anti-tumor effect against human cancer xenografts by a fully human monoclonal antibody to a variant 8-epitope of CD44R1 expressed on cancer stem cells. PLoS ONE 2012; 19: 387400.